ArticleResearch and practice in thrombosis and haemostasis2025
Joint health status in people with moderate hemophilia A: a cross-sectional multicenter study.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Use of the Multidimensional Haemophilia Pain Questionnaire (MHPQ) in Patients With Severe Haemophilia A Treated With Emicizumab: A Pilot Cross-Sectional, Single-Centre Study.Haemophilia : the official journal of the World Federation of HemophiliaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence of arthropathy in people with moderate hemophilia A (mHA) is highly variable. People with mHA are often undertreated, and this may lead to joint damage and worsen their quality of life. Objectives: The aim of the present study was to evaluate joint status in mHA by means of point-of-care ultrasound (PoCUS) and clinical examination. Methods: Consecutive people with mHA receiving on-demand replacement treatment underwent a clinical examination of joint status according to the Hemophilia Joint Health Score (HJHS) protocol. On the same day, all patients underwent a PoCUS assessment according to the Hemophilia Early Detection by UltraSound (HEAD-US) protocol. Results: A total of 51 subjects were included. The median HJHS score was 2.0 (IQR, 0-3.0). A 0 to 1 HJHS score was found in 23 people with mHA (45.1%), between 2 and 3 in 17 (33.3%) and >3 in 11 (21.6%). The median HEAD-US score was 2.0 (IQR, 1-7), and a statistically significant correlation between HJHS and HEAD-US was found (rho = 0.732; Conclusion: Our study suggests that the prevalence of arthropathy changes in people with mHA receiving on-demand treatment is not negligible and that PoCUS is able to detect osteochondral damage as well as HS in this clinical setting. A more extensive screening of the joint status could be useful to tailor treatment and improve outcomes in mHA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.